Petition to Establish the Advanced Approval Pathway for Longevity Medicines (AAPLM)
Congress, the Longevity Science Caucus (LSC), and Food and Drug Administration (FDA)
The AAPLM aims to incentivize the development and approval of drugs that target aging, the primary driver of chronic diseases that impair and kill millions of Americans each year. This proposal has the potential to improve individual health and autonomy, reduce healthcare costs, and generate substantial social and economic gains, making it an essential policy for the future of healthcare and society as a whole.
Sponsored by
To:
Congress, the Longevity Science Caucus (LSC), and Food and Drug Administration (FDA)
From:
[Your Name]
We, the undersigned, strongly support the establishment of the Advanced Approval Pathway for Longevity Medicines (AAPLM) as proposed by the Alliance for Longevity Initiatives (A4LI).
We believe that the AAPLM's three core provisions — with a special approval track, a priority review voucher system, and indication-by-indication patent term extensions — will encourage investment in the field, increase financial incentives, and facilitate clinical development of novel drugs for diseases with significant unmet medical needs.
By promoting the development and approval of groundbreaking longevity medicines, the AAPLM could improve individual health and autonomy, reduce healthcare costs, and generate substantial social and economic gains. Because the AAPLM has the potential to reduce healthcare costs, improve individual health and autonomy, and generate substantial social and economic gains, this policy reform is essential for the future of healthcare and society as a whole.
Therefore, we call upon Congress, the Longevity Science Caucus (LSC), and the Food and Drug Administration (FDA) to establish the AAPLM in order to accelerate the development and approval of longevity medicines. Thank you for your attention to this critical issue.